Saturday Morning

7:00 – 8:00  FULL BREAKFAST PROVIDED
Concourse Ballroom – Main Floor of Hotel

Galaxy Ballroom – 16th Floor – All Meeting Sessions for the day are in Galaxy Ballroom

8:00 – 8:45  INTRODUCTION AND KEYNOTE ADDRESS
Session Co-Chairs: Vladimir Hachinski & John Hallenbeck
• Welcome from the Conference Chair – Greg Albers
• Perspectives about STAIR and Stroke – Marc Fisher
• Keynote Lecture: The New Decade: Priorities and Opportunities for Acute Brain Ischemia Research – James Grotta

8:45 – 10:30  SESSION 1: IMPLEMENTATION & IMPACT of IV THROMBOLYSIS BEYOND 3 HRS
Session Co-Chairs: Susan Begelman, & Bruce Coull
• Benefits and Risk of IV Thrombolysis in 3-6 hr. Window – Kennedy Lees
• Use of tPA in Clinical Practice Beyond 3 Hrs: Market Penetration – Guidelines – Regulatory Approval – Dawn Kleindorfer
• Role of Advanced MR Imaging for Patient Selection Beyond 3 Hours – Steve Warach
• Role of Advanced CT Imaging for Patient Selection Beyond 3 Hours – Maarten Lansberg
ROUNDTABLE PANEL DISCUSSION: “CAN WE INCREASE UTILIZATION OF IV THROMBOLYSIS?”
John Marler & Max Wintermark

10:30 – 10:45  REFRESHMENT BREAK  Foyer Outside Galaxy Ballroom

10:45 – 12:30  SESSION 2: NON-PHARMACOLOGIC REPERFUSION STRATEGIES
Session Co-Chairs: Helmi Lutsep & Maria Sainz
• Current Status of Intra-Arterial Reperfusion Therapy: New Data, Markets & Reimbursement – Wade Smith
• Role of neuroimaging prior to intra-arterial therapy – Mike Lev
• Clinical Trials Using Mechanical Clot Retrievers: How Will We Determine Which Patients Benefit? – Tudor Jovin
• The SENTIS Trial: A Randomized Trial of a Mechanical Device – Andy Weiss
ROUNDTABLE PANEL DISCUSSION: “HOW WILL WE OPTIMIZE THESE TYPES OF THERAPIES?”
Andrei Alexandrov, Arani Bose, Michael Marks, Thomas Kent

12:30 – 1:30  LUNCH PROVIDED  Concourse Ballroom – Main Floor of Hotel
Saturday Afternoon

Galaxy Ballroom – 16th Floor

1:30 – 3:30  SESSION 3: CHALLENGES FOR BRAIN ISCHEMIA RESEARCH DUE TO REGULATORY AND REIMBURSEMENT DECISIONS
  Session Co-Chairs: Jackson Streeter & Joe Broderick
  • Considerations on Harmonizing FDA Device and Drug Approval Requirements – Billy Dunn
  • Devices in Acute Stroke: Paths to Market – Natalie Getzoff
  • How Can Clinical Trials Compete with Unproven but Reimbursed Devices? – Tony Furlan
  ROUNDTABLE PANEL DISCUSSION: PRIORITIES AND OPPORTUNITIES
  Thomas Barker, Avinoam Dayan, Malvina Eydelman, Ruchir Sehra & Marc Walton

3:30 – 3:45  REFRESHMENT BREAK  Foyer Outside Galaxy Ballroom

3:45 – 5:30  SESSION 4: NEUROPROTECTANTS FOR A NEW DECADE
  Session Co-Chairs: Harvey Altman & Justin Zivin
  • Acute Neuroprotective Strategies: Most Promising Agents Ready for Translation – Eng Lo
  • Why We Shouldn’t Abandon Neuroprotective Strategies – Sean Savitz
  • Neuroprotection to Prolong the Penumbra – Jeff Saver
  • Pharmacologic Agents to Enhance Recovery – Steve Cramer
  ROUNDTABLE PANEL DISCUSSION:
  Giora Feuerstein, Frank Sharp, Tom Jacobs & Mike Tymianski

6:30 – 7:00  SPONSORED RECEPTION – Sponsored by BioClinica
  Assembly Foyer – Main floor – Outside Commonwealth Ballroom

7:00 – 9:00  DINNER – Followed by Entertainment by Participants
  Cavalier Ballroom – Main Floor of Hotel
Sunday Morning, September 12

**7:00 – 8:00** BREAKFAST PROVIDED  
Concourse Ballroom – Main Floor of Hotel

*All Participants: Please Report Directly to Your Assigned Workshop at 8:00 AM*

**8:00 – 10:30** WORKSHOPS TO DEVELOP CONSENSUS RECOMMENDATIONS  
Participants are divided into three groups – each to develop recommendations

**WORKSHOP 1: RECOMMENDATIONS FOR IV THROMBOLYSIS:**  
*Cavalier A*  
**Optimizing the Use of IV Thrombolysis**  
*Main Floor*  
Facilitators: Larry Goldstein (Chair), Karen Furie & Phil Gorelick

**Considerations:**
- How do we maximize utilization of IV rt-PA?
- How do we find out which patients are most and least likely to benefit, especially in the 3-4.5 hour window?
- What are the advantages and disadvantages of the available techniques to select patients for late therapy (PWI/DWI, CTP, vessel occlusion, optimized clinical criteria)?
- What are the optimal study designs to expand the treatment window?
- Is a placebo still appropriate in a 3-4.5 hr time window study or should rt-PA be the standard therapy?
- Is the Primary Stroke Center concept working? How can it be improved?

**WORKSHOP 2: RECOMMENDATIONS FOR MECHANICAL REPERFUSION**  
*Cavalier B&C*  
**Establishing the Efficacy of Mechanical Reperfusion Therapies**  
*Main Floor*  
Facilitators: Larry Wechsler (Chair), David Liebeskind & Raul Nogueira

**Considerations:**
- What are the most important IA therapy questions to answer: how to prove efficacy?  
  – Which pts. benefit and which may be harmed? – Clarify how to optimally select pts? – Clarify time window?  
  – How to measure efficacy? – How to define reperfusion and SICH? – Should intubation be discouraged?
- Propose some feasible study designs, both randomized and non-randomized which address these issues.
- Discuss the statistical considerations for these study designs.
- Should the FDA mandate a randomized efficacy trial of mechanical clot removal?
- Should IV therapy be compared with IA therapy in the > 3 hr window?

**WORKSHOP 3: RECOMMENDATIONS FOR PROMISING NEUROPROTECTION APPROACHES**  
*North 1*  
**New Strategies To Achieve Proof Of Efficacy**  
*Main Floor*  
Facilitators: David Hess (Chair), Patricia Hurn & Jeff Saver

**Considerations:**
- Which neuroprotective strategies are most likely to be effective in humans for acute therapy?
- Which neuroprotective strategies are most likely to be effective in humans for enhancing recovery?
- Which changes in study design are most important to facilitate a positive trial in humans?
- Are there new paradigms to consider for neuroprotection to consider, i.e. penumbral extension and treating reperfusion injury?

**10:30 – 10:45** REFRESHMENT BREAK  
Assembly Foyer – Main floor – Outside Commonwealth Ballroom

**10:45 – 12:00** WORKSHOP CHAIRS PRESENT RECOMMENDATIONS – General Discussion  
*Galaxy Ballroom*  
Drafting of consensus statement is initiated – Chaired by Greg Albers

**12:00 – 12:15** CLOSING COMMENTS AND ADJOURNMENT